Following FDA, CHMP gives thumbs-up on Pfizer, BioNTech Omicron booster
One day after the FDA cleared Pfizer’s bivalent booster to go after Omicron, the pharma giant and its partners at BioNTech are now one step closer to an EU authorization.
Pfizer and BioNTech jointly announced Thursday that the EMA’s CHMP committee recommended conditional marketing authorization for the pair’s Comirnaty bivalent booster for Omicron to the European Commission. The bivalent booster, which would be approved in people ages 12 and up, targets both the wild-type SARS-CoV-2 virus and the Omicron subvariant BA.1.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.